ALEC logo

Alector, Inc. Common Stock

ALEC

ALEC: Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

more

Show ALEC Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of ALEC by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by ALEC's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Anti-siglec-9 antibodies and methods of use thereof Jun. 06, 2023
  • Patent Title: Anti-ms4a4a antibodies and methods of use thereof Jun. 06, 2023
  • Patent Title: Anti-trem2 antibodies and methods of use thereof Apr. 25, 2023
  • Patent Title: Anti-trem1 antibodies and methods of use thereof Oct. 18, 2022
  • Patent Title: Anti-ms4a4a antibodies and methods of use thereof Oct. 18, 2022
  • Patent Title: Transgenic mice expressing human trem proteins and methods of use thereof Oct. 18, 2022
  • Patent Title: Anti-tmem106b antibodies and methods of use thereof Sep. 13, 2022
  • Patent Title: Anti-sortilin antibodies and methods of use thereof Jul. 26, 2022
  • Patent Title: Anti-siglec-7 antibodies and methods of use thereof Jul. 19, 2022
  • Patent Title: Anti-siglec-5 antibodies and methods of use thereof Jun. 14, 2022
  • Patent Title: Methods of use of anti-sortilin antibodies for treating a disease, disorder, or injury May. 24, 2022
  • Patent Title: Anti-sirpa antibodies and methods of use thereof May. 03, 2022
  • Patent Title: Anti-cd33 antibodies and methods of use thereof Feb. 22, 2022
  • Patent Title: Methods of increasing progranulin levels using anti-sortilin antibodies Dec. 28, 2021
  • Patent Title: Isolated nucleic acids encoding anti-sortilin antibodies Nov. 30, 2021
  • Patent Title: Anti-cd33 antibodies and methods of use thereof Nov. 16, 2021
  • Patent Title: Siglec transgenic mice and methods of use thereof Oct. 19, 2021
  • Patent Title: Anti-cd33 antibodies and methods of use thereof Oct. 05, 2021
  • Patent Title: Anti-trem2 antibodies and methods of use thereof Aug. 10, 2021
  • Patent Title: Chimeric receptors and methods of use thereof Dec. 29, 2020
  • Patent Title: Methods of screening for sortilin binding antagonists Dec. 01, 2020
  • Patent Title: Anti-siglec-9 antibodies and methods of use thereof Oct. 13, 2020
  • Patent Title: Anti-cd33 antibodies and methods of use thereof Jul. 14, 2020
  • Patent Title: Anti-trem2 antibodies and methods of use thereof Jun. 09, 2020
  • Patent Title: Anti-siglec-7 antibodies and methods of use thereof Mar. 17, 2020
  • Patent Title: Anti-sortilin antibodies and methods of use thereof Oct. 01, 2019
  • Patent Title: Anti-sortilin antibodies and methods of use thereof Jun. 04, 2019
  • Patent Title: Anti-sortilin antibodies and methods of use thereof Oct. 02, 2018
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of ALEC in WallStreetBets Daily Discussion

ALEC News

Recent insights relating to ALEC

CNBC Recommendations

Recent picks made for ALEC stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ALEC

Corporate Flights

Flights by private jets registered to ALEC